Radiopharm Theranostics Ltd

Radiopharm is a company that has secured exclusive rights to various medical technologies through licensing agreements. Since November 2021, its ordinary shares have been listed on the ASX under the symbol "RAD". In July 2021, Radiopharm entered into an exclusive license agreement with NanoMab Technologies Limited, gaining exclusive rights to NanoMab's technology, specifically Anti-HER-2, Anti-TROP-2, Anti-PD-L1, and Anti-PTK7. This agreement involves upfront license fees, performance-based consideration tied to development milestones and commercial outcomes, and royalty payments based on net sales and sublicensing fees. Also in July 2021, Radiopharm secured exclusive rights to the Ga-Trivehexin technology developed by TRIMT GmbH. The terms included upfront license fees equivalent to US$10 million in cash and shares, performance-based consideration linked to development milestones and commercial outcomes, and net sales-based royalty payments and sublicensing fees. In September 2021, an exclusive license agreement with Diaprost AB and Fredax AB granted Radiopharm exclusive rights to Diaprost's technology. Additionally, in August 2021, Radiopharm entered into a license agreement with Cancer Research Technology Limited for the F-FPIA Imaging Agent, providing exclusive rights to develop and commercialize it for the diagnosis, imaging, prevention, and treatment of diseases. In November 2021, Radiopharm issued 20,000,000 convertible notes at A$1.00 per note to sophisticated investors, which were converted upon the completion of its initial public offering in Australia in 2021. In June 2022, Radiopharm entered into an exclusive sublicensing agreement with NeoIndicate, LLC, a U.S. company.